Calloway Nathaniel
Transaction: 04/04/2025
BUY
Change
+3,309
Price
$1.02
Filing
04/07/2025
Type
BUY
Anebulo Pharmaceuticals, Inc.
ANEB • Biotechnology
$0.36
▼ -0.03 (-7.95%)
Current price
EarningsLatest report: Dec 31, 2025
HIGHER-RISK PROFILECautionConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.
Market Cap
$14.75M
Growth
—
Cash Flow
0/5
Trend
Negative
Evidence
Manageable debt level · 0Healthy liquidity · 53.36Weak profitability
Financial data as of: Dec 31, 2025, 12:00 AM UTCLast earnings update: Feb 12, 2026, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:27 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$0.36
Change-7.95%
Shares Out41.08M
Market Cap$14.75M
Enterprise Value$5.71M
52W Range0.30 - 3.42
Beta-1.87
P/E-1.85
P/B1.86
P/FCF-2.53
EV/EBITDA-0.69
EV/FCF-0.98
Price$0.36
Change-7.95%
Shares Out41.08M
Market Cap$14.75M
Enterprise Value$5.71M
52W Range0.30 - 3.42
Beta-1.87
P/E-1.85
P/B1.86
P/FCF-2.53
EV/EBITDA-0.69
EV/FCF-0.98
Earnings Yield-54.10%
FCF Yield-39.60%
Dividend Yield0.00%
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Debt/Eq0.00
Current Ratio53.36
Quick Ratio53.36
Target$6.00
Target Upside1571.31%
Target Median$6.00
Target Range6.00 - 6.00
Volume1.64K
Avg Volume10.37K
EPS Surprise0.08
Investment DNA
How strong this company looks for long-term investors
42
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
70/100
Growth Potential
Revenue and expansion
50/100
Price Attractiveness
Cheap or expensive today
69/100
Why this score▼
Manageable debt level · 0Healthy liquidity · 53.36Weak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 4 analyst votes · 2026-09-05
88/100
Bullish
Bullish
3
Hold
1
Bearish
0
Price Target
2026-06-06
Low
$6.00
Mean
$6.00
Median
$6.00
High
$6.00
Insider Transactions
Recent executive and insider activity
Kupchyk Areta
Transaction: 04/04/2025
BUY
Change
+2,647
Price
$1.02
Filing
04/07/2025
Type
BUY
English Aron R.
Transaction: 04/04/2025
BUY
Change
+2,647
Price
$1.02
Filing
04/07/2025
Type
BUY
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| Calloway Nathaniel | BUY | +3,309 | $1.02 | 04/04/2025 | 04/07/2025 |
| Kupchyk Areta | BUY | +2,647 | $1.02 | 04/04/2025 | 04/07/2025 |
| English Aron R. | BUY | +2,647 | $1.02 | 04/04/2025 | 04/07/2025 |
| Lin Kenneth | BUY | +4,964 | $1.02 | 04/04/2025 | 04/07/2025 |
| Cunningham, Richard Anthony | BUY | +316,352 | $1.02 | 04/04/2025 | 04/07/2025 |
| Aryeh Jason | BUY | +4,964 | $1.02 | 04/04/2025 | 04/07/2025 |
| Cundy Kenneth C | BUY | +115,037 | $1.02 | 04/04/2025 | 04/07/2025 |
| SHAH BIMAL R. | BUY | +6,618 | $1.02 | 04/04/2025 | 04/07/2025 |
| Lawler Joseph F. | BUY | +13,236 | $1.02 | 04/04/2025 | 04/07/2025 |
| English Aron R. | BUY | +10,101,010 | $0.99 | 12/23/2024 | 12/26/2024 |
| Cunningham, Richard Anthony | BUY | +254,433 | $1.56 | 12/09/2024 | 12/10/2024 |
| Aryeh Jason | BUY | +2,482 | $2.10 | 06/13/2024 | 06/17/2024 |
| SHAH BIMAL R. | BUY | +3,309 | $2.10 | 06/13/2024 | 06/17/2024 |
| English Aron R. | BUY | +1,324 | $2.10 | 06/13/2024 | 06/17/2024 |
| Lawler Joseph F. | BUY | +6,618 | $2.10 | 06/13/2024 | 06/17/2024 |
| Kupchyk Areta | BUY | +1,324 | $2.10 | 06/13/2024 | 06/17/2024 |
| Calloway Nathaniel | BUY | +1,655 | $2.10 | 06/13/2024 | 06/17/2024 |
| Lin Kenneth | BUY | +2,482 | $2.10 | 06/13/2024 | 06/17/2024 |
| Cundy Kenneth C | BUY | +72,613 | $2.72 | 02/29/2024 | 03/08/2024 |
| Cundy Kenneth C | BUY | +72,613 | $2.78 | 02/29/2024 | 03/01/2024 |